scispace - formally typeset
Open AccessJournal ArticleDOI

Scientific Opinion on the substantiation of a health claim related to 3 g/day plant sterols/stanols and lowering blood LDL-cholesterol and reduced risk of (coronary) heart disease pursuant to Article 19 of Regulation (EC) No 1924/2006

Efsa Panel on Dietetic Products
- 16 May 2012 - 
- Vol. 10, Iss: 5, pp 2693
TLDR
In this paper, the authors provided a published systematic review and meta-analysis that evaluated the comparative efficacy of plant sterols and plant stanols for lowering blood LDL-cholesterol in healthy and hypercholesterolaemic subjects and an unpublished metaanalysis on 27 randomised controlled human studies on the LDL-lowering efficacy at a dose range between 2.6 and 3.4 g per day.
Abstract
Following an application from Unilever PLC and Unilever NV, submitted pursuant to Article 19 of Regulation (EC) No 1924/2006 via the Competent Authority of the United Kingdom, the Panel on Dietetic Products, Nutrition and Allergies was asked to deliver an opinion on the scientific substantiation of an application to modify the conditions of use of an authorised Article 14 claim related to 1.5 – 3.0 g plant sterols/stanols per day and lowering blood LDL-cholesterol by 7 – 12 % and reduced risk of (coronary) heart disease. The applicant has further requested that the minimum duration to obtain the effect be one to two weeks. The applicant provided a published systematic review and meta-analysis that evaluated the comparative efficacy of plant sterols and plant stanols for lowering blood LDL-cholesterol in healthy and hypercholesterolaemic subjects and an unpublished meta-analysis on 27 randomised controlled human studies on the LDL-lowering efficacy at a dose range between 2.6 and 3.4 g per day. On the basis of the data presented, the Panel concludes that plant sterols and stanol esters at daily intakes ranging from 1.5 to 3.0 g plant sterols/stanols in matrices approved by Regulation (EC) No 376/2010 (yellow fat spreads, dairy products, mayonnaise and salad dressings) have a similar efficacy on blood LDL-cholesterol lowering, that plant sterols and stanol esters at a daily intake of 3 g (range 2.6 g to 3.4 g) plant sterols/stanols in matrices approved by Regulation (EC) No 376/2010 lower LDL-cholesterol by 11.3 % (95 % CI: 10.0 – 12.5), and that the minimum duration required to achieve the maximum effect of plant sterols and stanols on LDL-cholesterol lowering is two to three weeks.

read more

Citations
More filters
Journal ArticleDOI

Cholesterol lowering with bile salt hydrolase-active probiotic bacteria, mechanism of action, clinical evidence, and future direction for heart health applications

TL;DR: This work reviews studies using BSH-active bacteria as cholesterol-lowering agents with emphasis on their cholesterol- Lowering mechanisms of action and describes the current treatments for CVD and the need for additional therapeutics.
Journal ArticleDOI

Effect of probiotics on biomarkers of cardiovascular disease: implications for heart‐healthy diets

TL;DR: The probiotic L. reuteri NCIMB 30242 was found to best meet TLC dietary requirements by significantly reducing LDL-C and total cholesterol, with robustness similar to that of existing TLC Dietary options, and improving other coronary heart disease risk factors, such as inflammatory biomarkers.
Journal ArticleDOI

Phytochemicals as modifiers of gut microbial communities.

TL;DR: The potential interactions between prominent phytochemicals and health benefits related to the GM are highlighted, emphasizing their potential as adjuvant strategies for GM-related diseases.
Journal ArticleDOI

Nutraceuticals for the treatment of hypercholesterolemia

TL;DR: The aim of this article is to review the main evidences supporting or denying the efficacy and safety of some of the most commonly used nutraceuticals with supposed cholesterol lowering activity.
References
More filters
Journal ArticleDOI

Meta-Analysis in Clinical Trials*

TL;DR: This paper examines eight published reviews each reporting results from several related trials in order to evaluate the efficacy of a certain treatment for a specified medical condition and suggests a simple noniterative procedure for characterizing the distribution of treatment effects in a series of studies.
Journal ArticleDOI

Plant sterol-enriched margarines and reduction of plasma total- and LDL-cholesterol concentrations in normocholesterolaemic and mildly hypercholesterolaemic subjects

TL;DR: A margarine with sterol-esters from soybean oil, mainly esters from sitosterol, campesterol and stigmasterol, is as effective as a margarines enriched with sitostanol-ester in lowering blood total- and LDL-cholesterol levels without affecting HDL-ch cholesterol concentrations.
Journal ArticleDOI

Continuous Dose-Response Relationship of the LDL-Cholesterol–Lowering Effect of Phytosterol Intake

TL;DR: The dose-dependent LDL-C-lowering efficacy ofphytosterols incorporated in various food formats was confirmed and equations of the continuous relationship were established to predict the effect of a given phytosterol dose.
Journal ArticleDOI

Modulation of plasma lipid levels and cholesterol kinetics by phytosterol versus phytostanol esters

TL;DR: The data indicate that plant sterol and stanol esters differentially lower circulating total and LDL cholesterol levels by suppression of cholesterol absorption in hypercholesterolemic subjects.
Journal ArticleDOI

Effects of 2 low-fat stanol ester–containing margarines on serum cholesterol concentrations as part of a low-fat diet in hypercholesterolemic subjects

TL;DR: It is concluded that the low-fat, plant stanol ester-containing margarines are effective cholesterol-lowering products in hypercholesterolemic subjects when used as part of a low-Fat, low-cholesterol diet.
Related Papers (5)